Updated regularly — Last updated June 2025
Wegovy UK: your complete, honest guide to semaglutide for weight loss
Wegovy has changed what's possible for people living with obesity in the UK. This guide covers everything honestly — what it is, how it works, what the clinical evidence shows, every side effect worth knowing about, how dosing works, NHS access, and what it costs privately. No commercial ties.
At a glance
Wegovy (semaglutide) is a once-weekly prescription injection for weight management in adults, made by Novo Nordisk. The familiar maintenance dose is 2.4mg weekly; the MHRA has also approved use up to 7.2mg weekly for adult patients with obesity where clinically appropriate and prescribed — see our Wegovy 7.2mg update. It activates GLP-1 receptors in the gut and brain to reduce appetite, slow digestion, and help you feel full on less food. In the landmark STEP-1 trial, participants lost an average of 15.2% of body weight over 68 weeks — a clinically meaningful result, and the strongest of any licensed weight-loss medication at the time of its approval. It is available via private prescription and through NHS specialist services for eligible patients.
Before buying Wegovy online, compare the full cost
Wegovy is a prescription-only medicine and should only be supplied through an appropriate UK pharmacy or prescribing service after a proper consultation. Before ordering, check the provider, the dose, the consultation process, the delivery charge and the total monthly price.
Why iGovy exists
iGovy was created to bring the same transparent, patient-first approach to Wegovy pricing that Monj brings to Mounjaro. It helps users compare UK Wegovy prices across providers and doses, without being pushed towards a single pharmacy through paid advertising or sponsored placement.
iGovy focuses on the full price picture, not just the cheapest-looking headline. That means helping users understand dose pricing, consultation costs, delivery fees, supply terms and the likely monthly cost before they order.
iGovy is built around cautious provider information, pharmacy checking and transparency. The aim is not just to list prices, but to help users ask better questions before buying from an online provider.
The iGovy approach is simple: clearer information, fewer hidden costs and better-informed choices for patients. It is designed for people who want to compare Wegovy safely and carefully, not for pharmacies trying to buy their way to the top of a list.
Why patients use iGovy to compare Wegovy prices
- Independent Wegovy price comparison
- UK patient-focused guidance
- Dose-by-dose pricing where available
- Consultation and delivery costs highlighted
- No paid pharmacy ranking
- Designed to reduce hidden-fee confusion
- Built around transparency and safer comparison
Why this matters when buying Wegovy online
Wegovy pricing can vary by dose, supply length, consultation model and delivery cost. iGovy helps users compare the likely total monthly cost rather than relying on a single promotional price.
What to check before ordering Wegovy online- Is the provider linked to an appropriate registered pharmacy or prescribing service?
- Is a proper consultation required before supply?
- Is the dose clearly shown?
- Does the price include consultation and delivery?
- Are discount terms clear?
- Is there a clear refund, cancellation or contact route?
- Does the website explain who is responsible for prescribing and dispensing?
What is Wegovy?
Wegovy is the brand name for semaglutide 2.4mg, a once-weekly prescription injection for weight management in adults. It is made by Novo Nordisk — a Danish pharmaceutical company that also makes Ozempic (semaglutide for type 2 diabetes) and Victoza (liraglutide). Wegovy received MHRA approval in the UK in 2023 and is now also covered by NICE guidance (TA875).
If you've heard of Ozempic and wondered about the relationship: they are the same active ingredient (semaglutide) but at different doses and with different licences. Ozempic is licensed for type 2 diabetes; Wegovy is licensed specifically for weight management, at a higher dose (up to 2.4mg vs Ozempic's maximum of 1mg). The dose matters — the additional weight-loss effect comes partly from the higher therapeutic dose. See our full Ozempic vs Wegovy guide →
How does Wegovy work?
Wegovy is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone produced naturally in your gut after eating. It signals fullness to the brain, slows the rate at which food moves through the stomach, and stimulates insulin release in response to food. By mimicking this hormone — but at a sustained, pharmacologically elevated level throughout the week — Wegovy keeps these signals active far beyond what natural GLP-1 would achieve.
In practical terms, people on Wegovy typically report that they feel satisfied after much smaller amounts of food, that the urge to eat between meals diminishes, and that food "cravings" — particularly for very high-calorie foods — become less insistent. Many describe a quiet but profound shift in their relationship with hunger. It is, for many people, the first time in their lives that eating less feels physiologically manageable rather than a constant battle.
Wegovy targets one receptor (GLP-1). Mounjaro (tirzepatide) targets two — GLP-1 and GIP. This dual mechanism is thought to explain why Mounjaro typically produces greater average weight loss in clinical trials. Full Mounjaro vs Wegovy comparison →
Clinical results — what to realistically expect
Wegovy's evidence base comes from the STEP (Semaglutide Treatment Effect in People with Obesity) programme — a series of large randomised controlled trials published in the New England Journal of Medicine. STEP-1 is the primary weight management trial:
| Group | Average weight loss (%) | Average weight lost (kg) | Achieving ≥15% loss |
|---|---|---|---|
| Wegovy 2.4mg | 15.2% | ~15.3 kg | 37% |
| Placebo (+ lifestyle) | 2.4% | ~2.4 kg | 8% |
Source: Wilding JPH et al., NEJM 2021 (STEP-1). Duration: 68 weeks. All participants followed a reduced-calorie diet and increased physical activity. Averages — individual results vary substantially.
Honest context on these numbers
15.2% is an average, and averages by definition include people who lose considerably more and people who lose less. About 1 in 3 participants lost more than 20%. Some people experience minimal weight loss on Wegovy — and understanding why (tolerance, dose, underlying metabolic factors) matters. Even a 5% weight loss carries clinically meaningful reductions in blood pressure, blood sugar, and joint load. Your prescriber can help you set realistic expectations for your individual circumstances.
Wegovy vs Mounjaro: key differences
The question we're asked most often about Wegovy. The short, honest answer: Mounjaro produces greater average weight loss in clinical trials; both are effective; individual response varies; neither is "better" — the right choice depends on your individual circumstances, your prescriber's assessment, and sometimes practical factors like cost and access.
| Factor | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP + GLP-1 agonist |
| Average weight loss | 15.2% (STEP-1) | 20.9% at 15mg (SURMOUNT-1) |
| Injection frequency | Once weekly | Once weekly |
| Pen type | FlexTouch (dial-and-click) | KwikPen (auto-injector) |
| NICE approval | TA875 (2023) | TA875 (2023) |
| Approx. private cost (starter) | ~£149–£165/month | ~£149–£165/month |
For a thorough, balanced analysis of both treatments — including clinical evidence, side effects, costs, and who might suit each — read our full Mounjaro vs Wegovy comparison.
Side effects — an honest overview
Wegovy's side effect profile is broadly similar to Mounjaro's, reflecting their shared GLP-1 mechanism, though there are some differences in incidence and quality of experience.
Very common (more than 1 in 10 people)
- Nausea — the most frequently reported side effect. Typically peaks in the first 4 weeks and improves with time. Eating smaller meals and avoiding fatty foods helps considerably.
- Diarrhoea — common especially early in treatment. Hydration is important.
- Constipation — some people experience this rather than diarrhoea. Fibre and fluids help.
- Vomiting — less frequent than nausea. Contact your prescriber if severe or persistent.
Common (1 in 10 to 1 in 100 people)
- Headaches — often related to changes in eating patterns or mild dehydration.
- Fatigue — frequently attributable to reduced calorie intake rather than direct drug effect.
- Abdominal discomfort — related to slowed gastric emptying.
- Injection site reactions — redness, bruising. Rotation of sites reduces these.
Worth knowing about — reported widely in practice
- Hair shedding — as with Mounjaro, this is almost always telogen effluvium from rapid weight loss, not a direct drug effect. Typically temporary. Full Wegovy side effects guide →
When to seek urgent medical advice
Stop Wegovy and seek urgent advice if you experience: severe persistent abdominal pain (possible pancreatitis); facial or throat swelling or difficulty breathing (allergic reaction); vision changes; or severe upper right abdominal pain (possible gallbladder issue). Always read the full patient information leaflet supplied with your medication.
Wegovy dosing and titration schedule
Like Mounjaro, Wegovy is started at the lowest dose and increased gradually over several months to minimise side effects. This titration process is important — please don't rush it.
| Phase | Weekly dose | Duration | Notes |
|---|---|---|---|
| Initiation | 0.25mg | 4 weeks | Adjustment only — not therapeutic. Do not skip. |
| Therapeutic 1 | 0.5mg | 4+ weeks | Appetite changes often begin here. |
| Therapeutic 2 | 1.0mg | 4+ weeks | Significant appetite reduction for many people. |
| Therapeutic 3 | 1.7mg | 4+ weeks | Increase only if tolerated well. |
| Maintenance | 2.4mg | Ongoing | Maximum licensed dose. Not everyone needs this level. |
If side effects are significant at a particular dose, staying at that level for longer before increasing is entirely appropriate. Discuss any concerns with your prescriber. See our full Wegovy dosing guide →
How to use the Wegovy FlexTouch pen
Wegovy uses a different injection device to Mounjaro. The FlexTouch pen has a dose selector that you turn to the correct dose, then press and hold the injection button until the dose counter returns to zero. Injection sites are the same as Mounjaro: abdomen, upper thigh, or outer upper arm.
Key steps: remove pen from fridge 30 minutes before use → clean skin with alcohol swab and allow to dry → select correct dose → press pen firmly at 90° → inject and hold until counter reaches zero → remove and dispose in sharps bin. Full illustrated guide at our Wegovy dosing guide →
Who is Wegovy suitable for?
Wegovy is licensed for adults with a BMI of 30+ (obesity), or BMI 27–29.9 with at least one weight-related health condition. The same criteria apply as for Mounjaro. A proper individual medical assessment by a registered prescriber is always required before starting.
Wegovy is not suitable for people who are pregnant, breastfeeding, or planning pregnancy; have a personal or family history of medullary thyroid carcinoma or MEN2; have a history of pancreatitis; or are under 18. Your prescriber will review your complete medical history and medications before prescribing.
NHS access in 2025
Wegovy received NICE approval (TA875) for NHS specialist weight-management services in 2023. Like Mounjaro, access through NHS GPs remains very limited. Most NHS access is through Tier 3 specialist services via GP referral, subject to BMI eligibility and a postcode lottery of ICB funding. The NHSE primary care pilot also covers Wegovy in some participating areas.
Our full NHS access guide covers eligibility criteria, how to approach your GP, how to check whether your ICB funds the service, and what to do if NHS access isn't yet available near you.
Private prescription costs for Wegovy in the UK
Wegovy is available via private prescription through GPhC-registered UK online pharmacies following a proper medical consultation.
| Dose | Approx. monthly cost | Notes |
|---|---|---|
| 0.25mg | ~£149–£165/month | Initiation only — not therapeutic |
| 0.5mg | ~£155–£175/month | First therapeutic dose |
| 1.0mg | ~£169–£195/month | — |
| 1.7mg | ~£185–£215/month | — |
| 2.4mg | ~£199–£239/month | Maintenance dose |
Approximate prices based on SlimBee market research, June 2025. Excludes consultation fee where charged separately. Verify current pricing directly. GBP (£) only. SlimBee earns no commission from any pharmacy.
Our guide to UK pharmacy types covers how to compare provider models safely. SlimBee does not endorse individual pharmacies — verify GPhC registration and read provider checks before paying.
Frequently asked questions about Wegovy
Same active ingredient (semaglutide), made by the same company (Novo Nordisk), but at different doses for different purposes. Ozempic is licensed for type 2 diabetes at up to 1mg. Wegovy is licensed specifically for weight management at up to 2.4mg. The higher dose in Wegovy produces meaningfully greater appetite-suppressing effects. Full Ozempic vs Wegovy comparison →
Most people notice reduced appetite within the first week or two. The 0.25mg initiation dose is for adjustment only — therapeutic appetite effects begin at 0.5mg. Meaningful weight loss typically becomes apparent from weeks 4–8. The full effect develops gradually as the dose increases over 16–20 weeks.
If fewer than 5 days have passed since your injection day: take it as soon as you remember, then resume your normal weekly schedule. If 5 or more days have passed: skip the missed dose and take your next one on your usual day. Never take two doses within 5 days of each other. If in doubt, contact your prescriber.
Unopened Wegovy pens should be stored in a refrigerator (2°C–8°C). Once removed from the fridge, pens can be kept at room temperature (below 30°C) for up to 28 days. Never freeze Wegovy. A frozen pen should be discarded. See our travel and storage guide →
Yes — the evidence consistently shows that significant weight regain occurs after stopping GLP-1 medications, as the appetite-suppressing effects end. The STEP 4 withdrawal trial showed participants regained about two-thirds of lost weight within 1 year of stopping. This is biology, not weakness. Planning what happens after treatment — ideally before you start — is essential. Your prescriber can help.
GLP Insights
Research context, not medical advice
In STEP 1, mean weight change at 68 weeks was about −14.9% with semaglutide 2.4 mg once weekly versus −2.4% with placebo in adults with obesity or overweight. Individual responses varied.
Source: Wilding et al., New England Journal of Medicine, 2021. Included for general context only; it does not mean this treatment is suitable for you.
Prescription weight-loss medicines require an individual assessment by an appropriate healthcare professional.
Related guides
Wegovy side effects guide
Complete and honest
Wegovy dosing guide
Every dose level covered
Mounjaro vs Wegovy
Full evidence comparison
NHS access guide
How to get it on the NHS
Compare pharmacy types
Choose a provider safely
Exercising on Wegovy
What the evidence says
Medical disclaimer: For informational purposes only. Wegovy (semaglutide 2.4mg) is a prescription-only medicine in the UK. Always consult a GMC-registered prescriber before starting, changing, or stopping medication. SlimBee has no commercial ties to any pharmacy. Last reviewed June 2025. References: Wilding JPH et al. NEJM 2021; NICE TA875; MHRA Wegovy product information. Full disclaimer →